These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 4069764)
1. Dialysis osteomalacia: a possible role for zirconium as well as aluminium. Ham KN; Brown DJ; Dawborn JK; Johnson CI; Nelson S; Xipell JM Pathology; 1985 Jul; 17(3):458-63. PubMed ID: 4069764 [TBL] [Abstract][Full Text] [Related]
2. The localization of aluminium and other elements in bone tissue of a case of renal osteodystrophy with an associated dialysis encephalopathy syndrome. McClure J; Smith PS J Pathol; 1984 Apr; 142(4):293-9. PubMed ID: 6716213 [TBL] [Abstract][Full Text] [Related]
3. Treatment of dialysis osteomalacia with desferrioxamine. Brown DJ; Dawborn JK; Ham KN; Xipell JM Lancet; 1982 Aug; 2(8294):343-5. PubMed ID: 6124756 [TBL] [Abstract][Full Text] [Related]
5. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ]. Jarava C; Armas JR; Palma A Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651 [TBL] [Abstract][Full Text] [Related]
6. Fluoride and strontium accumulation in bone does not correlate with osteoid tissue in dialysis patients. Cohen-Solal ME; Augry F; Mauras Y; Morieux C; Allain P; de Vernejoul MC Nephrol Dial Transplant; 2002 Mar; 17(3):449-54. PubMed ID: 11865091 [TBL] [Abstract][Full Text] [Related]
7. The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Slatopolsky E Kidney Int; 1987 Mar; 31(3):842-54. PubMed ID: 3573543 [No Abstract] [Full Text] [Related]
9. The use of intravenous and intraperitoneal desferrioxamine in aluminium osteomalacia. O'Brien AA; McParland C; Keogh JA Nephrol Dial Transplant; 1987; 2(2):117-9. PubMed ID: 3112649 [TBL] [Abstract][Full Text] [Related]
15. Aluminium-induced bone disease in uremic rats: effect of deferoxamine. Jablonski G; Klem KH; Danielsen CC; Mosekilde L; Gordeladze JO Biosci Rep; 1996 Feb; 16(1):49-63. PubMed ID: 8861540 [TBL] [Abstract][Full Text] [Related]
16. Pathophysiology and treatment of uremic bone disease. Coburn J; Kanis J; Popovtzer M; Ritz E; Slatopolsky E; Fleisch H Calcif Tissue Int; 1983 Sep; 35(6):712-4. PubMed ID: 6652544 [No Abstract] [Full Text] [Related]
17. Familial vitamin D deficient osteomalacia and renal osteodystrophy: shaping up the debate. Jabur WL Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):128-30. PubMed ID: 20061707 [TBL] [Abstract][Full Text] [Related]
18. Deferoxamine-induced bone changes in haemodialysis patients: a histomorphometric study. Charhon SA; Chavassieux P; Boivin G; Parisien M; Chapuy MC; Traeger J; Meunier PJ Clin Sci (Lond); 1987 Aug; 73(2):227-34. PubMed ID: 3652627 [TBL] [Abstract][Full Text] [Related]
19. Quantitation and localisation of aluminum in human cancellous bone in renal osteodystrophy. Boyce BF; Eider HY; Fell SG; Nicholson WA; Smith GD; Dempster DW; Gray CC; Boyle IT Scan Electron Microsc; 1981; (Pt 3):329-37. PubMed ID: 7330581 [TBL] [Abstract][Full Text] [Related]